The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis
No Thumbnail Available
Date
2022
Journal Title
Journal ISSN
Volume Title
Abstract
Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways. © 2022 American Academy of Allergy, Asthma & Immunology
Description
Keywords
Asthma , Disease Management , Humans , Mobile Applications , Rhinitis, Allergic , Telemedicine , antihistaminic agent , corticosteroid , dexamethasone , fluticasone furoate , fluticasone propionate , hydroxychloroquine , ivermectin , non prescription drug , sildenafil , allergic rhinitis , Article , asthma , controlled study , desensitization , disease exacerbation , disease severity , drug repositioning , health care access , health care delivery , health promotion , human , long term care , medicine , outcome assessment , patient care , peak inspiratory flow , prevalence , quality of life , questionnaire , randomized controlled trial , randomized controlled trial (topic) , social interaction , total quality management , visual analog scale , allergic rhinitis , asthma , disease management , mobile application , telemedicine